Understanding Medication-Assisted Treatment: Suboxone & Beyond

Medication-Assisted Treatment (MAT) with buprenorphine (Suboxone) is the most effective, evidence-based treatment available for opioid use disorder. Yet misconceptions and stigma continue to prevent people from accessing this life-saving therapy. Let me explain what MAT actually is, how it works, and why it matters.

What is Medication-Assisted Treatment?

Medication-Assisted Treatment (MAT) refers to the use of FDA-approved medications, combined with counseling and behavioral therapies, to treat substance use disorders. For opioid use disorder (OUD), the three primary MAT medications are buprenorphine (Suboxone), methadone, and naltrexone (Vivitrol).

MAT is endorsed by virtually every major medical organization: the American Society of Addiction Medicine (ASAM), SAMHSA, the CDC, the American Medical Association, and the World Health Organization. It is not a controversial treatment — it is the medical standard of care.

How Does Buprenorphine (Suboxone) Work?

Buprenorphine is a "partial opioid agonist" — it activates opioid receptors in the brain, but less so than full opioids like heroin or oxycodone. This partial activation:

• Eliminates withdrawal symptoms — Keeps the brain's opioid receptors satisfied so withdrawal doesn't occur
• Reduces cravings dramatically — The constant preoccupation with obtaining opioids is relieved
• Has a "ceiling effect" — Above a certain dose, more buprenorphine produces no additional euphoria, making it much safer than full agonists
• Blocks other opioids — At therapeutic doses, buprenorphine blocks the effects of other opioids, removing the incentive to use while on treatment

Suboxone also contains naloxone, an opioid antagonist, which prevents the medication from being misused by injection.

The Evidence Behind MAT

The evidence for MAT is overwhelming:

• MAT reduces opioid overdose mortality by 50% or more
• Patients on MAT are twice as likely to remain in treatment compared to non-medication approaches
• MAT is associated with significant reductions in illicit drug use, criminal activity, and HIV/hepatitis C transmission
• Patients on MAT have better employment rates, family function, and quality of life

Addressing the "Trading One Addiction for Another" Myth

One of the most damaging misconceptions about MAT is that it's "just trading one addiction for another." This is incorrect on several levels:

First, opioid use disorder is a brain disease. Just as we use insulin for diabetes or antihypertensives for hypertension without calling those patients "addicted" to their medications, buprenorphine treats a medical condition with medicine.

Second, patients on stable buprenorphine doses do not experience the rollercoaster of euphoria and withdrawal that characterizes active addiction. They function normally — working, parenting, driving, and living full lives.

Third, outcomes with MAT are dramatically better than without. "Abstinence-only" approaches without medication have relapse rates exceeding 80-90%, and each relapse in the fentanyl era carries a risk of fatal overdose.

Who Qualifies for MAT?

MAT is appropriate for adults who meet DSM-5 criteria for opioid use disorder — generally defined as 2 or more of the 11 diagnostic criteria. There is no requirement for prior detox, prior treatment failure, or minimum duration of opioid use. Dr. Kaura assesses each patient individually to determine the most appropriate MAT option.

MAT via Telehealth in Texas

Since 2023, federal regulations allow buprenorphine to be prescribed via telehealth without an in-person visit. At Synergy MD Clinic, we take full advantage of this to expand access to MAT for all Texas residents. You can start Suboxone treatment the same day as your telehealth consultation.

The Bottom Line

MAT saves lives. If you or someone you love is struggling with opioid addiction, please reach out. Effective, compassionate treatment is available — and you deserve it.